Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research News Agency

20 hours ago•Zacks Investment Research

General Medium Importance Neutral

Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates

Editas Medicine (EDIT) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.63 per share a year ago.

Source: Zacks Investment Research

Visit Source

0 0 0

Comment

Comments

No comments yet

Be the first person to comment on this news item.

Category General

Source Zacks Investment Research

Published 20 hours ago

Likes 0

Comments 0

Shares 0

News ID #1,426

Status Published

This news may have been collected automatically from third-party sources. Please verify important information through the original source and other reliable sources before making any trading or investment decision. This content is provided for informational purposes only and does not constitute financial advice.

Keep comments relevant to the news topic and avoid offensive, promotional, spam, or misleading content.

Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates

Comments

User Menu